Cardiff Oncology Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
CRDF$0.80+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Comprehensive Loss
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net loss | $(11,855) | $(9,731) | $(33,644) | $(32,104) |
| Other comprehensive loss: | ||||
| Unrealized gain (loss) on securities available-for-sale | 179 | 24 | 149 | (12) |
| Total comprehensive loss | (11,676) | (9,707) | (33,495) | (32,116) |
| Preferred stock dividend payable on Series A Convertible Preferred Stock | (6) | (6) | (18) | (18) |
| Comprehensive loss attributable to common stockholders | $(11,682) | $(9,713) | $(33,513) | $(32,134) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.